Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension

NCT04218552 is registered in ClinicalTrials.gov with Addpharma Inc. as lead sponsor.

NCT NCT04218552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04218552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension
Lead sponsor
Addpharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 25, 2020
Completion date
February 25, 2021
Enrollment
176 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension,essential